TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Teledermatology Mobile App: Patient Facing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The inclusion criterion for the trial with direct to patient facing apps was that a site had greater than or equal to 9% of all Fiscal Year (FY) 2018 dermatology encounters under secondary stop codes 695/696.~* This indicated considerable pre-existing experience with consultative teledermatology and the likely presence of dermatology reader and support personnel needed to implement direct to patient facing apps.~* The investigators identified 31 sites eligible for direct to patient facing apps.~* We followed above criteria but due to low enrollment, an additional criteria was added that patients were included if they received a request to use the patient-facing mobile app.~Exclusion Criteria:~* VA medical centers with no 695/696 stop code activity in FY2018 or with zero full-time equivalent dermatologists were excluded since these sites likely lacked the expertise, support, and infrastructure to feasibly adopt teledermatology during the study period.~* The investigators also excluded sites outside the continental U.S., and sites without a dermatology clinic.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Rural Veterans (Type: None): Originally the aim was to include VA sites who received the direct to patient facing app from OCC. Due to a lack of enrollment, the first arm or group has been redefined as Veterans living in rural areas receiving a request to use the patient facing app.
- Nonrural Veterans (Type: None): Originally the comparison group consisted of VA sites to eventually receive the direct to patient facing apps. Since our enrollment at the facility level was low, this arm now consists of Veterans receiving a request to use the patient facing app, living in nonrural areas.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II patients~* aged 2-6 years~* patient scheduled for elective tonsillectomy due to recurrent~* chronic tonsillitis~Exclusion Criteria:~* patients with known hypersensitivity to medication drugs~* coagulation disorders~* thrombocytopenia~* significant cardiac~* renal~* pulmonary~* hepatic disease

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- DEX I (Type: ACTIVE_COMPARATOR): active comparator receive 0.5µg/kg dexmedetomidine orally half an hour before operation
- Saline Control (Type: PLACEBO_COMPARATOR): 2ml oral 0.9%saline half an hour before operation
- DEX II (Type: ACTIVE_COMPARATOR): active comparator receive,1µg/kg dexmedetomidine orally half an hour before operation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Detemir Action in Cerebro

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetic patients;~* Diabetes duration =/\> 1 year;~* HbA1c \~ 7,5%;~Exclusion Criteria:~* Recent onset of DM;~* BMI \< 18 OR \> 35 kg/m2;~* T2DM;~* History of major heart/renal disease;~* Severe untreated proliferative retinopathy;~* History of recurrent severe hypoglycaemia;~* (History of) brain disorders;~* Alcohol abuse,(History of) drug abuse, benzodiazepines, selective beta-blockers, oral steroids, oral anticoagulants;~* Current psychiatric disease/treatment;~* (history of) eating disorders;~* History of severe head trauma accompanied by loss of consciousness;~* Any endocrine disease not well controlled for at least 3 months;~* Inability to undergo MRI;~* Visual acuity \< 0.3;~* Known or suspected allergy to trial product or related products

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Receipt of at least 1 dose of investigational product (etanercept) and participation for approximately 96 weeks in study 0881A1-3338 (B1801014)~Personally signed and dated informed consent document (and assent document, as applicable) indicating the subject (or legally representative/guardian) has been informed of all pertinent aspects of the study.~Exclusion Criteria:~Exclusion criteria for subject planning to continue investigational product:~withdrawal from investigational product in study 0881A1-3338 for any reason (safety or non-safety).~History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma in situ.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment With Antimalarials in Kenyan Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Presenting for Pentavalent 1 immunization~* Age 5 weeks to 16 weeks~* Parent or guardian currently resident in study catchment area~* Parent or guardian has given permission for their child to participate~Exclusion Criteria:~* Known allergy to any of the study drugs~* Current Cotrimoxazole prophylaxis~* Concomitant disease requiring hospitalization or transfusion~* Plans to be away from the study area for more than 6 months during the next year

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 16 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female pediatric ESRD, Patients \>_ 2 and \<_ 16 years of age, whose legally authorized representative provided signed informed consent.~* Stabilized on chronic hemodialysis therapy with an identified need for maintenance iron therapy.~* Predetermined TSAT and serum Ferritin (at the screening visit).~* Receiving a stable EPO dosing regimen.~Exclusion Criteria:~* Receipt of any form of iron supplementation during the 2 weeks prior to the first Ferrlecit dosing.~* Hypersensitivity to Ferrlecit or any of its inactive components.~* High TSAT level.~* High Serum Ferritin

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Scheduled cesarean section delivery~* Patient of TriHealth's Faculty Medical Center or Tri-State Maternal Fetal Medicine Associates~* Singleton pregnancy~* Term delivery (greater than or equal to 37 weeks)~* Spinal/epidural anesthesia with epidural analgesia (duramorph)~* Use of pfannenstiel incision~Exclusion Criteria:~* Weight less than 50 kg~* Allergy to study drugs (acetaminophen, oxycodone, duramorph, NSAIDS)~* Multiple gestation pregnancy~* Cesarean section for pre-term delivery (less than 37 weeks)~* Fetal anomalies~* Inability to use epidural duramorph at time of procedure~* General anesthesia used~* Vertical skin incision~* Opioid addiction~* Liver dysfunction (hepatitis, HELLP (hemolysis, elevated liver enzymes, and low platelet count), preeclampsia)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Acetaminophen (Type: EXPERIMENTAL): Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
- Normal Saline (Type: PLACEBO_COMPARATOR): Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Psoriatic arthritis (PsA) diagnosed \> 6months prior~* Active PsA at the time of screening and at baseline visits, with \>= 3 swollen joints and \>= 3 tender joints~* Have at least 1 of the PsA subsets (DIP joint arthritis, polyarticular arthritis without rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis)~* Active plaque psoriasis with a lesion \>= 2cm in diameter~* Active arthritis despite current disease modifying anti-rheumatic drug (DMARD) or nonsteroidal anti-inflammatory drug (NSAID) therapy~* Stable doses of methotrexate, low-dose corticosteroids, and NSAIDs are permitted.~Exclusion Criteria:~* No prior treatment with biologic anti-TNF agents (infliximab, etanercept, adalimumab)~* No treatment with alefacept or efalizumab within 3 months prior to the first study drug injection~* No DMARDs other than methotrexate, or immunosuppressive drugs within 4 weeks prior to the first study drug injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
- 001 (Type: EXPERIMENTAL): Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
- 003 (Type: EXPERIMENTAL): golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy children and infants aged from 2 months to less than 6 years as established by medical history and clinical examination.~2. The subjects' parents/guardians are able to understand and sign the ICF.~Exclusion Criteria:~1. Age \< 2 months or ≥ 6 years.~2. For subjects \< 1 year, gestational age \< 34 weeks or birth weight \< 2200 grams.~3. Has poor venous access (for subjects in sub-study only).~4. Currently has a fever defined as ear/rectal temperature ≥ 38°C or axillary temperature ≥ 37.5 °C within 2 days before the time of planned vaccination.~5. Has had previous known exposure to EV71 or has received EV71 vaccine.~6. Has a history of herpangina or HFMD associated with enterovirus infection in the past 30 days before the date of the planned study drug vaccination.~7. Has been diagnosed with a significant neurological, pulmonary, cardiovascular, hematological, hepatic, or renal disorder.~8. Has a history of hypersensitivity to vaccines, or a history of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~9. Has used any investigational/non-registered product (including drug, vaccine, or invasive medical device) within 28 days before vaccination or plan to use during the study period.~10. Has confirmed or suspected autoimmune disorder, or immunodeficiency.~11. Administration of any licensed live attenuated vaccine within 14 days before or after each study vaccination (with the exceptions of live attenuated Rotavirus vaccine via oral route).~12. Has used immunoglobulins or any blood products within 11 months before vaccination or plan to use during the whole study period.~13. Has had immunosuppressants, cytotoxic drugs, corticosteroids (including prednisolone ≥ 0.5 mg/kg/day or equivalent), or immunomodulators taken for \> 14 days within 6 months before first vaccination or plan to use before the last scheduled study visit. (Inhaled and topical steroids are allowed).~14. Has any medical or psychiatric condition, that is a contraindication to protocol participation based on the judgment of the Investigator.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- EV71vac (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or above~2. Adequate hematologic, hepatic, and renal function~3. Histologically confirmed, new diagnosis of PTCL~4. Eligible for CHOP regimen~5. Measurable disease based on Cheson 2007 criteria~6. Eastern Cooperative Oncology Group (ECOG) performance status \< 2~7. Willing to perform at least two methods of contraception~8. Negative pregnancy test of females with childbearing potential.~Exclusion Criteria:~1. Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life threatening disease. If there is a history of prior malignancies or life threatening diseases, the patient must be disease free for at least 5 years.~2. Congestive heart failure Class III/IV according to the New York Heart Association (NYHA) Functional Classification.~3. Uncontrolled hypertension~4. Central nervous system (CNS) metastases .~5. Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment~6. Major surgery within 30 days prior to enrollment.~7. Use of any investigational drugs, biologics, or devices within 30 days prior or during the study treatment.~8. Previous exposure to pralatrexate.~9. Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Dose Finding, Cohort 1 (Type: EXPERIMENTAL): Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated written informed consent.~* Male or female patients diagnosed with type 1 diabetes (T1D) at least 6 months prior to informed consent or type 2 diabetes (T2D) or non-diabetic obese patients.~* T1D patients must use and be willing of and be willing to continue throughout the duration of the trial either:~* multiple daily injections of insulin OR~* continuous sub-cutaneous insulin infusion of any insulin type, with at least 3 months experience~* For patients with T1D or T2D,HbA1c of 6.5 - 11%~* Age at least 18 years of age~* Body mass index of \>=18.5 kg/m\^2~* Estimated glomerular filtration rate greater than or equal to 60 ml/min/1.73m2~* Blood pressure greater than 90 /60 mmHg and less than or equal to 140 / 90 mmHg~* Use of a highly effective method of contraception.~* Further inclusion criteria apply~Exclusion criteria:~* For patients with T1D, treatment with an antihyperglycaemic agent within 3 months prior to visit 1~* occurrence of severe hypoglycaemia within 3 months prior to visit 1~* hypoglycaemic unawareness within 3 months prior to visit 1~* occurrence of diabetic ketoacidosis within 3 months of visit 1 and until visit 3 Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: EXPERIMENTAL): Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
- Sequence B (Type: EXPERIMENTAL): Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Short-term Antibiotic for Pyelonephritis in Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women between 18 and 65 years old~* Diagnosis of Acute Uncomplicated Pyelonephritis~* Patient obliged to participate in the French national health and pensions system.~* Patient who have read, understood and signed the consent~Exclusion Criteria:~* Women who are pregnant~* Men~* One of these risk factor who define a complicated pyelonephritis:~Medical history of uro-nephrology problem Nephropathy Obstructive Uropathy Vesicoureteral reflux Post mictinal residue \> 100mL Urinary fistula Catheter vesicle and urethral Kidney transplantation Immunodeficiency Diabetes~* Recurrent pyelonephritis~* Allergy of betalactam or cephalosporin~* History of hypersensitivity reactions to antibiotic medications~* Patient in terminal care~* Trouble of cognitive function~* Patient deprive of judicial or administrative freedom~* Patient participating to another trial~* Refusal to participate to the trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete